Karus Therapeutics develops small‑molecule PI3K p110‑delta/beta and HDAC6 inhibitor programmes targeting inflammatory disease and cancer. Its molecules are reported to display high potency and specificity and show oral activity in preclinical models of inflammatory disease. Karus highlights potential applications in arthritis and other inflammatory conditions and plans to explore PI3K inhibitors for PTEN‑negative tumours and patient‑stratified cancer therapies. The company intends to advance its proprietary programmes through early clinical trials. Karus is UK‑based (Southampton, England), privately held, and described as having a strong financial track record and experienced investors. The company also announced an expanded board following the financing.

Total raised

$8M

Funding rounds

1

Latest round

Series B

Latest activity

Sep 2012